Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?

Mutagenesis

Volumn 28, Issue 6, 2013, Pages 625-629

  Gupta, Satish ^a,b   Jaworska Bieniek, Katarzyna ^a,b   Lubinski, Jan ^a   Jakubowska, Anna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 2; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE PEROXIDASE 6; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; SELENIUM; SELENOPROTEIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; DNA DAMAGE; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; MISSENSE MUTATION; OXIDATION REDUCTION REACTION; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SPERMATOZOON MATURATION; THYROID CANCER;

CHECKPOINT KINASE 2; DIETARY SUPPLEMENTS; HUMANS; MUTATION; NEOPLASMS; SELENIUM; SELENOPROTEINS; SIGNAL TRANSDUCTION;

EID: 84888583959     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/get050     Document Type: Review

References (57)

1. Rayman, M. P. (2000) The importance of selenium to human health. Lancet, 356, 233-241.
2. Letavayová, L., Vlcková, V. and Brozmanová, J. (2006) Selenium: from cancer prevention to DNA damage. Toxicology, 227, 1-14.
3. Seo, Y. R., Kelley, M. R. and Smith, M. L. (2002) Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc. Natl. Acad. Sci. USA, 99, 14548-14553.
4. Harris, H. R., Bergkvist, L. and Wolk, A. (2012) Selenium intake and breast cancer mortality in a cohort of Swedish women. Breast Cancer Res. Treat., 134, 1269-1277.
5. Jaworska, K., Gupta, S., Durda, K., et al. (2013) A low selenium level is associated with lung and laryngeal cancers. PLoS One, 8, e59051.
6. Amaral, A. F., Cantor, K. P., Silverman, D. T. and Malats, N. (2010) Selenium and bladder cancer risk: A meta-analysis. Cancer Epidemiol. Biomarkers Prev., 19, 2407-2415.
7. Lener, M. R., Gupta, S., Scott, R. J., et al. (2013) Can selenium levels act as a marker of colorectal cancer risk? BMC Cancer, 13, 214.
8. Yu, M. W., Horng, I. S., Hsu, K. H., Chiang, Y. C., Liaw, Y. F. and Chen, C. J. (1999) Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am. J. Epidemiol., 150, 367-374.
9. Wei, W. Q., Abnet, C. C., Qiao, Y. L., et al. (2004) Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am. J. Clin. Nutr., 79, 80-85.
10. Glattre, E., Thomassen, Y., Thoresen, S. O., Haldorsen, T., Lund-Larsen, P. G., Theodorsen, L. and Aaseth, J. (1989) Prediagnostic serum selenium in a case-control study of thyroid cancer. Int. J. Epidemiol., 18, 45-49.
11. Brinkman, M., Reulen, R. C., Kellen, E., Buntinx, F. and Zeegers, M. P. (2006) Are men with low selenium levels at increased risk of prostate cancer? Eur. J. Cancer, 42, 2463-2471.
12. Duffield-Lillico, A. J., Reid, M. E., Turnbull, B. W., Combs, G. F. Jr, Slate, E. H., Fischbach, L. A., Marshall, J. R. and Clark, L. C. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev., 11, 630-639.
13. Lippman, S. M., Klein, E. A., Goodman, P. J., et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301, 39-51.
14. Reszka, E. (2012) Selenoproteins in bladder cancer. Clin. Chim. Acta., 413, 847-854.
15. Kumaraswamy, E., Malykh, A., Korotkov, K. V., et al. (2000) Structureexpression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J. Biol. Chem., 275, 35540-35547.
16. Rebsch, C. M., Penna, F. J. 3rd and Copeland, P. R. (2006) Selenoprotein expression is regulated at multiple levels in prostate cells. Cell Res., 16, 940-948.
17. Fang, W., Goldberg, M. L., Pohl, N. M., Bi, X., Tong, C., Xiong, B., Koh, T. J., Diamond, A. M. and Yang, W. (2010) Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis, 31, 1360-1366.
18. Lincoln, D. T., Al-Yatama, F., Mohammed, F. M., Al-Banaw, A. G., Al-Bader, M., Burge, M., Sinowatz, F. and Singal, P. K. (2010) Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Anticancer Res., 30, 767-775.
19. Udler, M., Maia, A. T., Cebrian, A., et al. (2007) Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J. Clin. Oncol., 25, 3015-3023.
20. Cadenas, C., Franckenstein, D., Schmidt, M., et al. (2010) Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res., 12, R44.
21. Penney, K. L., Schumacher, F. R., Li, H., et al. (2010) A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev. Res. (Phila)., 3, 604-610.
22. Steinbrecher, A., Méplan, C., Hesketh, J., Schomburg, L., Endermann, T., Jansen, E., Akesson, B., Rohrmann, S. and Linseisen, J. (2010) Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol. Biomarkers Prev., 19, 2958-2968.
23. Méplan, C., Hughes, D. J., Pardini, B., et al. (2010) Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis, 31, 1074-1079.
24. Peters, U., Chatterjee, N., Hayes, R. B., Schoen, R. E., Wang, Y., Chanock, S. J. and Foster, C. B. (2008) Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., 17, 1144-1154.
25. Ratnasinghe, D., Tangrea, J. A., Andersen, M. R., Barrett, M. J., Virtamo, J., Taylor, P. R. and Albanes, D. (2000) Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res., 60, 6381-6383.
26. Jablonska, E., Gromadzinska, J., Sobala, W., Reszka, E. and Wasowicz, W. (2008) Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur. J. Nutr., 47, 47-54.
27. Hammond, E. M., Freiberg, R. A. and Giaccia, A. J. (2006) The roles of Chk 1 and Chk 2 in hypoxia and reoxygenation. Cancer Lett., 238, 161-167.
28. Bartek, J., Falck, J. and Lukas, J. (2001) CHK2 kinase-a busy messenger. Nat. Rev. Mol. Cell Biol., 2, 877-886.
29. Mariotti, M., Lobanov, A. V., Guigo, R. and Gladyshev, V. N. (2013) SECISearch3 and Seblastian: new tools for prediction of SECIS elements and selenoproteins. Nucleic Acids Res., 41, e149.
30. Bell, D. W., Varley, J. M., Szydlo, T. E., et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286, 2528-2531.
31. Shaag, A., Walsh, T., Renbaum, P., et al. (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum. Mol. Genet., 14, 555-563.
32. Cybulski, C., Górski, B., Huzarski, T., et al. (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet., 75, 1131-1135.
33. CHEK2 Breast Cancer Case-Control Consortium. (2004) CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am. J. Hum. Genet., 74, 1175-1182.
34. Bogdanova, N., Enssen-Dubrowinskaja, N., Feshchenko, S., et al. (2005) Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer, 116, 263-266.
35. Cybulski, C., Wokołorczyk, D., Huzarski, T., et al. (2007) A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland. Breast Cancer Res. Treat., 102, 119-122.
36. Weischer, M., Nordestgaard, B. G., Pharoah, P., et al. (2012) CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J. Clin. Oncol., 30, 4308-4316.
37. Teodorczyk, U., Cybulski, C., Wokołorczyk, D., et al. (2013) The risk of gastric cancer in carriers of CHEK2 mutations. Fam. Cancer, [Epub ahead of print], doi:10.1007/s10689-012-9599-2.
38. Wasielewski, M., Vasen, H., Wijnen, J., Hooning, M., Dooijes, D., Tops, C., Klijn, J. G., Meijers-Heijboer, H. and Schutte, M. (2008) CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Clin. Cancer Res., 14, 4989-4994.
39. Kilpivaara, O., Vahteristo, P., Falck, J., et al. (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer, 111, 543-547.
40. Cybulski, C., Wokołorczyk, D., Kładny, J., et al. (2007) Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur. J. Hum. Genet., 15, 237-241.
41. Cybulski, C., Wokołorczyk, D., Jakubowska, A., et al. (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J. Clin. Oncol., 29, 3747-3752.
42. Brennan, P., McKay, J., Moore, L., et al. (2007) Uncommon CHEK2 missense variant and reduced risk of tobacco-related cancers: case control study. Hum. Mol. Genet., 16, 1794-1801.
43. Cybulski, C., Masojc, B., Oszutowska, D., et al. (2008) Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis, 29, 762-765.
44. Gronwald, J., Cybulski, C., Piesiak, W., et al. (2009) Cancer risks in firstdegree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br. J. Cancer, 100, 1508-1512.
45. Kilpivaara, O., Bartkova, J., Eerola, H., et al. (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumocharacteristics among unselected breast cancer patients. Int. J. Cancer, 113, 575-580.
46. Oldenburg, R. A., Kroeze-Jansema, K., Kraan, J., et al. (2003) The CHEK2*1100delC variant acts as a breast cancer risk modifier in non- BRCA1/BRCA2 multiple-case families. Cancer Res., 63, 8153-8157.
47. Khan, N., Afaq, F. and Mukhtar, H. (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal., 10, 475-510.
48. Ohno, Y., Fukuda, K., Takemura, G., et al. (1999) Induction of apoptosis by gallic acid in lung cancer cells. Anticancer. Drugs, 10, 845-851.
49. Ou, T. T., Wang, C. J., Lee, Y. S., Wu, C. H. and Lee, H. J. (2010) Gallic acid induces G2/M phase cell cycle arrest via regulating 14-3-3β release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells. Mol. Nutr. Food Res., 54, 1781-1790.
50. Lee, S. M., Li, M. L., Tse, Y. C., Leung, S. C., Lee, M. M., Tsui, S. K., Fung, K. P., Lee, C. Y. and Waye, M. M. (2002) Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway. Life Sci. 71, 2267-2277.
51. Ou, T. T., Wu, C. H., Hsu, J. D., Chyau, C. C., Lee, H. J. and Wang, C. J. (2011) Paeonia lactiflora Pall inhibits bladder cancer growth involving phosphorylation of Chk2 in vitro and in vivo. J. Ethnopharmacol., 135, 162-172.
52. Yin, M. B., Li, Z. R., Cao, S., Durrani, F. A., Azrak, R. G., Frank, C. and Rustum, Y. M. (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression. Mol. Pharmacol., 66, 153-160.
53. Dong, Y., Zhang, H., Hawthorn, L., Ganther, H. E. and Ip, C. (2003) Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res., 63, 52-59.
54. Jerome-Morais, A., Bera, S., Rachidi, W., Gann, P. H. and Diamond, A. M. (2013) The effects of selenium and the GPx-1 selenoprotein on the phosphorylation of H2AX. Biochim. Biophys. Acta, 1830, 3399-3406.
55. Wu, M., Kang, M. M., Schoene, N. W. and Cheng, W. H. (2010) Selenium compounds activate early barriers of tumorigenesis. J. Biol. Chem., 285, 12055-12062.
56. Qi, Y., Schoene, N. W., Lartey, F. M. and Cheng, W. H. (2010) Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells. J. Biol. Chem., 285, 33010-33017.
57. Papp, L. V., Lu, J., Holmgren, A. and Khanna, K. K. (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal., 9, 775-806.